©2019 by Ben-David Lab.

CRACKING CANCER ANEUPLOIDY

Our lab focuses on a unique, understudied trait of cancer. Changes in the chromosomal composition of the cell, also known as aneuploidy, make for a fundamental difference between normal and cancer cells. We combine experimental and computational approaches to uncover the basic biology underlying this hallmark of cancer, track its origins and understand its cellular consequences. By doing so, we strive to expand our understanding of the genetic basis of cancer, and to make aneuploidy a therapeutic target for precision cancer medicine.

 

OUR RESEARCH INTERESTS

 

CANCER ANEUOPLIDY

Aneuploidy – the presence of an abnormal number of chromosomes in cancer cells — is characteristic of most tumors, and is rarely observed in normal tissues. It is not fully understood how aneuploidy contributes to tumor formation and progression. Moreover, there are currently no therapeutics that target this hallmark of cancer to  eliminate tumors. We apply a variety of genomic and functional approaches to studying this phenomenon.

EVOLUTION OF CANCER MODELS

The study of the complex genetics of human cancer depends on reliable cancer model systems. However, these models reflect the biology of actual human tumors only to a certain extent, and they evolve in ways that pose both risks and opportunities for cancer research. We study the genomic stability and evolution of cancer model systems, in order to improve their use in basic research, with an emphasis on aneuploidy research.

STEM CELLS & CANCER

Human stem cells share fundamental characteristics with human cancer cells, and thus make for a unique model system for the study of cancer genetics. We use human stem cells as a tool for aneuploidy research, taking advantage of their inherent chromosomal instability and of their amenability to genome editing.  We also use human stem cells as a tool for the identification of cancer vulnerabilities.

 

OUR BIG QUESTIONS

WHAT DRIVES ANEUPLOIDY IN CANCER? HOW DOES ANEUPLOIDY CONTRIBUTE TO THE INITIATION AND PROGRESSION OF TUMORS?

WHAT CELLULAR VULNERABILITIES ARE INDUCED BY ANEUPLOIDY? HOW CAN ANEUPLOIDY BE EXPLOITED TO KILL CANCER CELLS?

WHAT ARE THE IMPLICATIONS OF GENOMIC EVOLUTION FOR CANCER MODELING? HOW CAN CANCER MODEL SYSTEMS BE IMPROVED?

 

LAB NEWS

WATCH DR. BEN-DAVID'S TALK AT:

WORLD CANCER DAY, 2020

February 3, 2020

WELCOME TO JOHANNA AND LIHY, WHO ARE JOINING OUR LAB THIS MONTH!

January 1, 2020

THE LAB IS AWARDED THE 'ISRAEL CANCER ASSOCIATION' 2020 RESEARCH GRANT

January 6, 2020

RENOVATIONS ARE OVER. WE'VE JUST MOVED TO OUR NEW LAB. COME VISIT US ON THE 7TH FLOOR OF THE SACKLER BUILDING!

December 30, 2019

WELCOME TO TOM AND KAVYA, WHO ARE JOINING OUR LAB THIS MONTH!

December 15, 2019

DR. BEN-DAVID IS AWARDED THE TAU 'CANCER BIOLOGY RESEARCH CENTER' (CBRC) RESEARCH GRANT FOR 2020

October 16, 2019

CHECK OUT OUR NEW REVIEW ARTICLE ON CANCER ANEUPLOIDY, JUST PUBLISHED IN NATURE REVIEW GENETICS

September 23, 2019

DR. BEN-DAVID IS AWARDED THE 'RICHARD EIMERT RESEARCH FUND ON SOLID TUMORS' IN COLLABORATION WITH DR. AMIR SONNENBLICK

August 7, 2019

DR. BEN-DAVID IS AWARDED THE 'AZRIELI FACULTY FELLOWSHIP'

June 16, 2019

 

RESEARCH FUNDING

 
 

ADDRESS

Faculty of Medicine, Room 728
Tel Aviv University
P.O.B 39040
Ramat Aviv, Tel Aviv 69978

CONTACT


ubendavid@tauex.tau.ac.il

+972-(0)73-3804730

+972-(0)54-6004444